BioStock: Alligator Bioscience’s CEO on the rights issue
Alligator Bioscience is developing tumour-directed antibody-based treatments against cancer. At the beginning of the year, the company reported positive interim results from the OPTIMIZE-1 phase II study in pancreatic cancer with lead candidate mitazalimab. Since then, Alligator has not slowed down. The company is now carrying out a rights issue of approximately SEK 199 million. Alligator's CEO Søren Bregenholt visited the BioStock Studio to tell us more.Watch the interview with Søren Bregenholt at biostock.se: Alligator Bioscience’s CEO on the rights issue - BioStock